Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: fecal calprotectin.
- Who it may be relevant to
- Registry conditions: Esophageal Varices. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Accuracy of Fecal Calprotectin in Detecting Esophageal Varices in Egyptian Patients With Liver Cirrhosis
Overview
The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients. Researchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices. Participants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.
Interventions
- Diagnostic test fecal calprotectin
fecal calprotectin test measures calprotectin protein in a stool sample. fecal calprotectin acts as a surrogate for gastrointestinal inflammation (e.g., inflammatory bowel disease, infectious gastroenteritis, acute appendicitis, peptic ulcer disease, coeliac disease, non-steroidal anti-inflammatory drugs (NSAID)-induced enteropathy)
Primary outcome measures
- measuring fecal calprotectin level (microgram/gram) for predicting esophageal varices [Time frame: through study completion, an average of 1 year]
Secondary outcome measures (1)
- comparing fecal calprotectin versus non-invasive scores for predicting esophageal varices [Time frame: through study completion, an average of 1 year]
Eligibility criteria
Inclusion criteria
- Age ≥18 years
- Liver cirrhosis
Exclusion criteria
- Patients aged < 18 years.
- Inflammatory bowel disease.
- Infectious gastroenteritis.
- Malignancy.
- Patients on proton pump inhibitors or NSAID.
- Patients with spontaneous bacterial peritonitis.
- Patients with hepatic encephalopathy.
- Unwilling to participate in our study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Ecologic or community
Study locations
Egypt · 1 center
- Tanta University Hospitals — Tanta
Identifiers
NCT: NCT06908798 · 36264PR983/12/24